Antibodies for Glioma Markers

Atlas Antibodies offer antibodies targeting several proteins relevant for glioma characterization, including ATRX, IDH1, and GFAP.

Glioma is a common type of brain tumor, that springs from glial cells. The tumor type comprises about 80% of all malignant brain tumors and often carry a very poor prognosis. Gliomas can be categorized depending on different factors such as grade, cell type, location, and genetics.

Based on genetics, research has shown that gliomas could be classified into three groups based on mutations in ATRX, IDH1, and 1p/19q:

ATRX, a marker for glioma

ATRX is one of the routine markers for classification of gliomas and is most often used in combination with various other markers such as IDH1, P53, PARP1, GFAP, KI-67, and EGFR2.

Multiplexed IHC-IF staining of glioblastoma multiforme (left) and oligodendroglioma (right)
Multiplexed IHC-IF staining of glioblastoma multiforme (left) and oligodendroglioma (right) showing ATRX (red) and IDH1 (green) immunoreactivity in tumor cells using Anti-ATRX antibody (left: HPA001906, right: AMAb90784, clone 0537) and Anti-IDH1 antibody (AMAb90578, clone 0219). Nuclei were counterstained with DAPI.

Antibodies targeting glioma markers

Our antibodies targeting the glioma markers ATRX, IDH1 and GFAP used in the images to detect Glioblastoma, Oligodendroglioma, and Astrocytomas are validated for IHC, WB and/or ICC-IF. The antibodies have been validated using enhanced validation in IHC or WB. For more details on each antibody, click the respective links below to visit the product pages.

Anti-ATRX monoclonal antibody (AMAb90784)        

  • validated for IHC, WB, ICC-IF
  • sequence identity mouse/rat 96%/97%

Anti-ATRX polyclonal antibody (HPA001906)

  • IHC, WB
  • sequence identity mouse/rat 96%/97%

Anti-ATRX polyclonal antibody (HPA064684)

  • validated for ICC-IF
  • sequence identity mouse/rat 51%/57%

Anti-IDH1 monoclonal antibody (AMAb90578)        

  • validated for IHC, WB, ICC-IF
  • sequence identity mouse/rat 95%/95%

Anti-IDH1 polyclonal antibody (HPA035248)

  • validated for IHC, WB
  • sequence identity mouse/rat 95%/95%

Anti-IDH1 polyclonal antibody (HPA057936)

  • validated for IHC, WB
  • sequence identity mouse/rat 92%/95%

Anti-GFAP monoclonal antibody (AMAb91033)       

  • validated for IHC, WB, ICC-IF
  • sequence identity mouse/rat 98%/100%

Anti-GFAP polyclonal antibody (HPA056030)

  • validated for IHC, WB, ICC-IF
  • sequence identity mouse/rat 98%/100%

Anti-GFAP polyclonal antibody (HPA063513)

  • validated for IHC
  • sequence identity mouse/rat 100%/98%
Multiplexed IHC-IF staining of oligodendroglioma using Anti-ATRX antibody (AMAb90784) and Anti-GFAP antibody (AMAb91033)
Multiplexed IHC-IF staining of oligodendroglioma showing ATRX (nuclear, red) and GFAP (cytoplasmic, green) immunoreactivity in tumor cells using Anti-ATRX antibody (AMAb90784) and Anti-GFAP antibody (AMAb91033). Nuclei were counterstained with DAPI.

References

The following citations uses Anti-ATRX Antibody (HPA001906) in glioma:

Haberler C et al. Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas. Clin Neuropathol2014; 33(2):108-111.

Oktay Y et al., IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation Sci Rep, 2016 Jun 10; 6:27569.

Murnyák B et al. PARP1 expression and its correlation with survival is tumor molecular subtype dependent in glioblastomaOncotarget, 2017 May 19; 8(28):46348-46362. 

Rosager AM et al. Expression and prognostic value of JAM-A in gliomas. J Neurooncol , 2017 Jul 4; 135(1):107-117.

Lee Y et al.  e frequency and prognostic e ect of TERT promoter mutation in di use gliomas. Acta Neuropathol Commun, 2017 Aug 29; 5:62. 

Valentini MC et al. Comparison among conventional and advanced MRI, 18F-FDG PET/CT, phenotype and genotype in glioblastoma. Oncotarget, 2017 Oct 4; 8(53):91636-91653. 

Li X et al. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss. Sci Rep , 2017 Oct 12; 7:13038.